Skip to main content

Forty51 closes first fund totaling 43 million US dollars

| News

Forty51 closes first fund totaling 43 million US dollars

19.07.2022

A new Basel-based venture fund, Forty51 Ventures I, has raised a total of 43 million US dollars following a first fund closing. Forty51 invests in European biotech firms with clear clinical pathways. The first investment took the form of early stage financing for Mosanna Therapeutics from Basel.

Forty51 Ventures has announced the first closing of its Biotech Venture Capital Fund I and its first investment. In a press release, the company provides details in connection with a deal worth 43 million US dollars. The core strategy of the company, which was founded in Basel in April 2022, aims to support the founding of start-ups and early stage investments in the biotechnology sector, primarily in Switzerland, France and Germany.

The fund, which is based in Luxembourg, is being advised by a three-strong founding team who boast an extensive network and decades of experience in the area of drug development, transactions and venture capital. In addition, the team works with prominent figures within the industry and a strategic partner in the USA.

Investment in biotech

In addition to the closing, Forty51 has also announced its first investment. Mosanna Therapeutics, a biotech firm also recently founded in Basel, is the beneficiary of this. Forty51 led this early stage financing round. The consortium of investors also includes the London-based firm Stable Asset Management and the Fischli family. Mosanna is working on a small molecule developed by Sanofi to treat patients with metabolic obstructive sleep apnea.

“Forty51 Ventures brings true company building to Europe’s exciting Biotech scene”, comments Erik Serrano-Berntsen, CEO and founder of Stable Asset Management, in the press release. “I have not come across a truly differentiating investment strategy in biotech coupled with such a highly complementary skillset among the founding partners”, he concludes.

 

Learn more about Life Sciences in Switzerland

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.